The term "Goodpasture's" disease is reserved for individuals who have disease in association with antibodies to the glomerular basement membrane (GBM), either bound directly to the target organ or in the circulation. Diagnosis is based on the demonstration of anti-GBM antibodies, either in the ...
Evolution of antiglomerular basement membrane glomerulonephritis into membranous glomerulonephritis Antiglomerular basement membrane glomerulonephritis (anti-GBM GN) is a rare disease characterized by autoantibodies to the alpha 3 chain of type IV collage... N Hecht,A Omoloja,D Witte,... - 《Pediatric...
We have compared the effect of therapy with immunosuppression alone to immunosuppression plus plasma exchange on the clinical course and rate of disappearance of antibody in 17 patients with anti-glomerular basement membrane (anti-GBM) a... JP Johnson,J Moore,HA Austin,... - 《Medicine》 被引...
Sertraline is included as one of the CUSP9 drugs based on its good tolerability and demonstrated antiglioma effects [69]. A clinical trial of CUSP9 combined with TMZ for the treatment of recurrent GBM has just been completed and disclosed clinically desirable safety and efficacy (NCT02770378; ...
(Fig.6b, c). The body weight of mice had a slight increase for HM-NPs@G while a subsequent and sharp reduction for TMZ and PBS treatments, supporting the effective anti-GBM effects of HM-NPs@G (Fig.6d). Importantly, the median survival time of mice treated with HM-NPs@G (65 d) ...
Glioblastoma multiforme (GBM) is characterized as a highly invasive, aggressive brain tumor1. Individuals with GBM face a poor prognosis, with few surviving past the 2-year mark1,2. A combination of chemotherapy, surgical resection, and radiotherapy is the gold standard for glioblastoma therapy, ...
“Integrated proteogenomic characterization of glioblastoma evolution,” in which they concluded, “Our work uncovers the proteomic and phosphoproteomic changes leading to GBM recurrence and provides insights that can be used for diagnostics and precision therapeutics to prevent and/or delay drug resi...
International Society for Extracellular Vesicles PMN: Pre-metastatic niche EGFRvIII: Expression of epidermal growth factor receptor variant III GBM: Glioblastoma ECM: Extracellular matrix EGF: Epidermal growth factor VEGF: Vascular endothelial growth factor HSC: Hematopoietic stem cells DC: Dendr...
Concurrent TMZ/IR followed by adjuvant TMZ is standard-of-care for GBM patients, thus the addition of a PARP inhibitor may provide a therapeutic benefit. ABT-888 is a potent PARP inhibitor targeting both PARP-1 and PARP-2, is orally bioavailable and demonstrates blood–brain barrier penetration...
Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer 2013; 1: 21. PubMed PubMed Central Google Scholar Bullain SS, Sahin A, Szentirmai O, Sanchez C, Lin N, ...